Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Product Briefs: Hearing Device; Volcano’s iFR Modality; St. Jude Pain Device

This article was originally published in The Gray Sheet

Executive Summary

FDA approved Cochlear Ltd.’s Nucleus Hybrid L24 cochlear implant system, the first implantable device for adults with severe or profound sensorineural hearing loss. Volcano’s instant wave-Free Ratio (iFR) intravascular imaging modality is cleared based on ADVISE II results. More product news.

You may also be interested in...

FDA Approval Listing: Three Original PMAs In March

FDA posted its official listing of March PMAs this week, including original PMA approvals for devices from Abbott Laboratories, Cochlear Ltd. and Roche Diagnostics. Also, average time-to-decision data for PMA supplements.

News Briefs: Panel Supports Cochlear Implant; ReShape Duo Trial Update; Medtronic’s D-fib Lead Software

FDA panel supports cochlear implant device. ReShape Medical’s ReShape Duo intragastric balloon meets its primary efficacy endpoints in the REDUCE trial. Medtronic gains FDA approval of defibrillator lead software. More news.

ProNova Preps Its Next-Gen SC360 For Smaller, Cheaper Era Of Proton Therapy

The system, which developers hope to launch in the U.S. in 2015 following completion of a 510(k) submission to FDA, will cost about $50 million for a two-room configuration, and the gantry will weigh 15 tons, well under the typical 110-220-ton weight of most systems, according to ProNova.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts